Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...
Inquirer on MSN2d
Controlled drug Ketamine a lifeline for patients with severe depression in S’poreKetamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
14h
California gastroenterologist Dr. Saurabh Sethi has called out three popular drinks that increase the risk of Alzheimer’s.
US Weekly on MSN6d
What Celebrities and Doctors Have Said About Ketamine Use: Chrissy Teigen, Matthew Perry, MoreCelebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what ...
Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback